Qualitative or quantitative protein defects in neuromuscular diseases
MONDO:001613930 clinical trials for this condition and its sub-types, 0 tagged with Qualitative or quantitative protein defects in neuromuscular diseases itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Qualitative or quantitative protein defects in neuromuscular diseases
-
Sarcoglycanopathy 3 trials · 10 incl. sub-types
4 sub-types
- Qualitative or quantitative defects of beta-sarcoglycan 0 trials · 5 incl. sub-types Sub-types →
- Qualitative or quantitative defects of gamma-sarcoglycan 1 trial · 4 incl. sub-types Sub-types →
- Qualitative or quantitative defects of alpha-sarcoglycan 0 trials · 3 incl. sub-types Sub-types →
- Qualitative or quantitative defects of delta-sarcoglycan 0 trials · 2 incl. sub-types Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan 0 trials · 8 incl. sub-types
1 sub-type
- Qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan 0 trials · 8 incl. sub-types Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of dystrophin 4 trials · 5 incl. sub-types
2 sub-types
-
Neuromuscular disease caused by qualitative or quantitative defects of titin 0 trials · 4 incl. sub-types
1 sub-type
- TTN-related myopathy 2 trials · 4 incl. sub-types Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of tropomyosin 0 trials · 4 incl. sub-types
5 sub-types
- TPM2-related myopathy 1 trial · 3 incl. sub-types Sub-types →
- Childhood-onset nemaline myopathy 1 trial · 2 incl. sub-types Sub-types →
- TPM3-related myopathy 1 trial Sub-types →
- Intermediate nemaline myopathy 0 trials Sub-types →
- Typical nemaline myopathy 0 trials Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of dysferlin 0 trials · 3 incl. sub-types
4 sub-types
-
Neuromuscular disease caused by qualitative or quantitative defects of alpha-actin 0 trials · 2 incl. sub-types
5 sub-types
- Childhood-onset nemaline myopathy 1 trial · 2 incl. sub-types Sub-types →
- Severe congenital nemaline myopathy 0 trials · 1 incl. sub-types Sub-types →
- Adult-onset nemaline myopathy 0 trials
- Intermediate nemaline myopathy 0 trials Sub-types →
- Typical nemaline myopathy 0 trials Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of nebulin 0 trials · 2 incl. sub-types
5 sub-types
- Childhood-onset nemaline myopathy 1 trial · 2 incl. sub-types Sub-types →
- Severe congenital nemaline myopathy 0 trials · 1 incl. sub-types Sub-types →
- Adult-onset nemaline myopathy 0 trials
- Intermediate nemaline myopathy 0 trials Sub-types →
- Typical nemaline myopathy 0 trials Sub-types →
-
Collagen 6-related myopathy 1 trial
3 sub-types
- Bethlem myopathy 1A 0 trials
- Ullrich congenital muscular dystrophy 1A 0 trials
- Myosclerosis 0 trials
-
Neuromuscular disease caused by qualitative or quantitative defects of myofibrillar proteins 0 trials · 1 incl. sub-types
4 sub-types
- Qualitative or quantitative defects of desmin 0 trials · 1 incl. sub-types Sub-types →
- Qualitative or quantitative defects of alphaB-cristallin 0 trials
- Qualitative or quantitative defects of filamin C 0 trials Sub-types →
- Qualitative or quantitative defects of protein ZASP 0 trials Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of plectin 0 trials · 1 incl. sub-types
2 sub-types
-
Neuromuscular disease caused by qualitative or quantitative defects of selenoprotein N1 0 trials · 1 incl. sub-types
2 sub-types
- Multiminicore myopathy 1 trial Sub-types →
- Rigid spine syndrome 0 trials · 1 incl. sub-types Sub-types →
-
Neuromuscular disease caused by qualitative or quantitative defects of telethonin 0 trials · 1 incl. sub-types
2 sub-types
-
Alpha-actinopathy 0 trials
4 sub-types
- Cap myopathy 0 trials
- Congenital myopathy 2a, typical, autosomal dominant 0 trials
- Progressive scapulohumeroperoneal distal myopathy 0 trials
- Zebra body myopathy 0 trials
-
Caveolinopathy 0 trials
1 sub-type
-
2 sub-types
-
3 sub-types
- MYH7-related skeletal myopathy 0 trials
- Congenital myopathy 7A, myosin storage, autosomal dominant 0 trials
- Hyaline body myopathy 0 trials
-
2 sub-types
-
2 sub-types
- Brody myopathy 0 trials
- Myopathy due to calsequestrin and SERCA1 protein overload 0 trials
Most studied deeper sub-types
-
Hope for rare muscle disease: new drug enters final testing phase
Disease control OngoingThis study tests a drug called BBP-418 (Ribitol) in 81 people aged 12 to 60 with limb girdle muscular dystrophy type 2I (LGMD2I), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo for 36 months to see if it slows the di…
Phase 3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Gene therapy trial offers hope for rare muscle disease
Disease control OngoingThis study tests a single dose of a gene therapy called AB-1003 in 10 adults with a rare genetic muscle disease (LGMD2I/R9). The goal is to see if it is safe and can help improve muscle function. Participants must be able to walk or run 10 meters in under 30 seconds.
Phase 1/2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental drug targets root cause of rare muscle-wasting disease
Disease control OngoingThis study tests an experimental drug, BBP-418, in people with limb girdle muscular dystrophy type 2I (LGMD2I), a rare genetic condition that causes progressive muscle weakness. The drug aims to fix a molecular defect by helping a faulty enzyme work better. The trial includes bot…
Phase 2 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Hope for muscle strength: experimental drug tested for Long-Term use in rare muscular dystrophy
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called BBP-418 (ribitol) in people with limb-girdle muscular dystrophy type 2I/R9, a rare genetic muscle-weakening disease. Participants who completed a previous study will take BBP-418 orally twice d…
Phase 3 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One-Time gene therapy aims to halt rare muscle disease
Disease control OngoingThis study tests a single dose of SRP-9003 gene therapy in 17 people with limb girdle muscular dystrophy 2E/R4, a genetic muscle-weakening disease. The goal is to restore a missing protein in muscle cells and improve muscle function. Both walkers and non-walkers can join, and the…
Phase 3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental gene therapy targets rare muscle disease in first human test
Disease control OngoingThis early-phase trial tests a single-dose gene therapy called SRP-9003 in 6 people with limb girdle muscular dystrophy type 2E/R4, a rare genetic muscle-weakening disease. The main goals are to check safety and see if the therapy can produce the missing beta-sarcoglycan protein …
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene therapy hope for kids with rare muscle-wasting disease
Disease control OngoingThis early-stage trial tests a single intravenous dose of a gene therapy (ATA-200) in 4 children aged 6-12 with limb-girdle muscular dystrophy type 2C/R5 (LGMD2C), a rare genetic muscle-weakening condition. The goal is to see if the treatment is safe and tolerable by delivering a…
Phase 1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene therapy targets rare muscle disease
Disease control OngoingThis early-stage trial tests a gene therapy called ATA-100 for people with LGMDR9, a rare genetic muscle disease that causes progressive weakness. Six adults receive a single intravenous infusion of the therapy, which delivers a working copy of the FKRP gene. The main goal is to …
Phase 1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a common asthma drug help newborns breathe easier?
Symptom relief OngoingThis phase 3 trial tests whether inhaled salbutamol, a drug used for asthma, can help newborns with transient tachypnoea (rapid breathing after birth). About 608 babies born between 32 and 42 weeks will receive either salbutamol or a placebo. The goal is to see if the drug reduce…
Phase 3 • Sponsor: Medical University of Warsaw • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Researchers hunt for muscle clues in rare dystrophy
Knowledge-focused OngoingThis pilot study looks at biomarkers in the blood of people with fragile sarcolemmal muscular dystrophy, a condition that makes muscle membranes weak. Researchers will collect blood samples at rest and after exercise during four 5-day hospital stays. The goal is to better underst…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists watch LGMD progress in 205 patients over years
Knowledge-focused OngoingThis study follows 205 people with four types of limb-girdle muscular dystrophy (LGMD) to understand how the disease changes over time. Participants will have their muscle strength, movement, and breathing tested regularly for up to 5 years. No treatment is given; the goal is to …
Sponsor: Sarepta Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New study aims to map rare muscle disease progression
Knowledge-focused CancelledThis study was designed to track the natural course of gamma-sarcoglycanopathy (LGMDR5), a rare muscle-weakening disease, over two years. Researchers planned to measure changes in muscle strength, walking ability, and daily function in patients aged 6 to 35. The goal was to bette…
Sponsor: Atamyo Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC